Close Menu

NEW YORK (GenomeWeb News) – Citing expected organic growth and a continuing ramp up of QIAsymphony, investment bank JP Morgan today upgraded Qiagen to Overweight.

In a research note, analyst Tycho Peterson upgraded the firm from Neutral and estimated full-year 2012 revenues at $1.25 billion and adjusted earnings per share at $1.01. He maintained a December 2012 price target of $19.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.